ACUTE EFFECTS OF OLANZAPINE ON PLASMA LEPTIN, GLUCOSE TOLERANCE FREE FATTY ACIDS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 动物数据表明，奥氮平通过改变瘦素水平而导致体重增加。这项研究的目的是确定奥氮平的急性效应是否降低了受试者的血浆瘦素和改变了糖耐量。 这项研究将招募大约32名健康志愿者，年龄在18-30岁之间，体重指数在20-25之间，没有精神障碍或慢性病，接受为期3天的奥氮平或安慰剂治疗，一周后交叉接受相反的治疗。受试者将在GCRC就诊前的3天内每天服用一片。在此期间，他们将遵循3天300克的碳水化合物饮食。受试者将完成饥饿调查，进行游离脂肪酸、葡萄糖、胰岛素和瘦素的血液测试，然后接受口服葡萄糖耐量测试。这些相同的程序将在1-2周后重复。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Animal data suggest that olanzapine induces weight gain by alterations in leptin levels. The goal of this study is to determine if the acute effects of olanzapine is to attenuate plasma leptin and alter glucose tolerance in human subjects. This study will enroll approximately 32 healthy volunteers ages 18-30, with BMI 20-25 without psychiatric disorders or chronic disease to receive 3 days of treatment with 10 mg olanzapine or placebo, then crossed over after one week to receive the opposite treatment. Subjects will take one pill daily for the 3 days up to the GCRC visit. During this time they will follow a 3 day 300g carbohydrate diet. Subjects will complete surveys of their hunger, have blood tests for free fatty acids, glucose, insulin and leptin and then undergo the oral glucose tolerance test. These same procedures will be repeated 1-2 weeks later.